• 4943 Citations
  • 38 h-Index
20032024

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Area of Expertise

The O’Bryant laboratory is dedicated to precision medicine in Alzheimer’s disease and other neurodegenerative diseases, including Down syndrome, Lewy Body disease, Parkinson’s disease, traumatic brain injury, and others. The fully translational lab has a Biomarker Core (Dr. Hall, Director), Clinical Core (Dr. Johnson, Director), Administrative Core (Dr. O’Bryant, Director) and Data Core (Dr. Johnson, Director). The lab also has a Neuroimaging Core (USC, Dr. Toga, Director). Dr. O’Bryant's multiple NIH grants focus on novel strategies for disease detection, screening into trials (therapeutic and prevention), and patient stratification for optimal treatment response. As part of this work, the lab has a strong focus on the impact of ethnicity/diversity on cognitive loss during the aging process and runs the one-of-a-kind Health & Aging Brain among Latino Elders (HABLE) study, which is the most comprehensive study of Mexican-American brain aging to date.

Education/Academic qualification

PhD in Clinical Psychology, University at Albany

Award Date: 1 Jan 2002

MA in Clinical Psychology, University at Albany

Award Date: 1 Jan 2001

BS in Psychology, Louisiana State University

Award Date: 1 Jan 2000

Fingerprint Dive into the research topics where Sid O'Bryant is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 12 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Research Output

A proteomic signature for dementia with Lewy bodies

O'Bryant, S. E., Ferman, T. J., Zhang, F., Hall, J., Pedraza, O., Wszolek, Z. K., Como, T., Julovich, D., Mattevada, S., Johnson, L. A., Edwards, M. & Graff-Radford, N. R., Dec 2019, In : Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 11, p. 270-276 7 p.

Research output: Contribution to journalArticle

Open Access
  • 1 Scopus citations

    Assessing Neuronal and Astrocyte Derived Exosomes From Individuals With Mild Traumatic Brain Injury for Markers of Neurodegeneration and Cytotoxic Activity

    Winston, C. N., Romero, H. K., Ellisman, M., Nauss, S., Julovich, D. A., Conger, T., Hall, J. R., Campana, W., O’Bryant, S. E., Nievergelt, C. M., Baker, D. G., Risbrough, V. B. & Rissman, R. A., 2 Oct 2019, In : Frontiers in Neuroscience. 13, 1005.

    Research output: Contribution to journalArticle

    Open Access
  • Author Correction: Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (Nature Genetics, (2019), 51, 3, (414-430), 10.1038/s41588-019-0358-2)

    Alzheimer Disease Genetics Consortium (ADGC), The European Alzheimer’s Disease Initiative (EADI), Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE) & Genetic and Environmental Risk in AD/Defining Genetic, Polygenic and Environmental Risk for Alzheimer’s Disease Consortium (GERAD/PERADES), 1 Sep 2019, In : Nature Genetics. 51, 9, p. 1423-1424 2 p.

    Research output: Contribution to journalComment/debate

    Open Access
  • Blood-based biomarkers for Down syndrome and Alzheimer's disease: A systematic review

    Petersen, M. E. & O'Bryant, S., 1 Jul 2019, In : Developmental Neurobiology. 79, 7, p. 699-710 12 p.

    Research output: Contribution to journalReview article

  • 3 Scopus citations

    Blood Biomarkers for Use in Alzheimer Disease - Moving from "if" to "how?"

    O'Bryant, S. E., Sep 2019, In : JAMA Neurology. 76, 9, p. 1009-1010 2 p.

    Research output: Contribution to journalEditorial

    4 Scopus citations